These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24628546)

  • 1. Development and characterization of a differentiated thyroid cancer cell line resistant to VEGFR-targeted kinase inhibitors.
    Isham CR; Netzel BC; Bossou AR; Milosevic D; Cradic KW; Grebe SK; Bible KC
    J Clin Endocrinol Metab; 2014 Jun; 99(6):E936-43. PubMed ID: 24628546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
    Cabanillas ME; de Souza JA; Geyer S; Wirth LJ; Menefee ME; Liu SV; Shah K; Wright J; Shah MH
    J Clin Oncol; 2017 Oct; 35(29):3315-3321. PubMed ID: 28817373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New therapies for dedifferentiated papillary thyroid cancer.
    Fallahi P; Mazzi V; Vita R; Ferrari SM; Materazzi G; Galleri D; Benvenga S; Miccoli P; Antonelli A
    Int J Mol Sci; 2015 Mar; 16(3):6153-82. PubMed ID: 25789503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.
    Kim KB; Cabanillas ME; Lazar AJ; Williams MD; Sanders DL; Ilagan JL; Nolop K; Lee RJ; Sherman SI
    Thyroid; 2013 Oct; 23(10):1277-83. PubMed ID: 23489023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.
    Beadnell TC; Mishall KM; Zhou Q; Riffert SM; Wuensch KE; Kessler BE; Corpuz ML; Jing X; Kim J; Wang G; Tan AC; Schweppe RE
    Mol Cancer Ther; 2016 Aug; 15(8):1952-63. PubMed ID: 27222538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations.
    Russo MA; Kang KS; Di Cristofano A
    Thyroid; 2013 Oct; 23(10):1284-93. PubMed ID: 23509868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.
    Bible KC; Suman VJ; Molina JR; Smallridge RC; Maples WJ; Menefee ME; Rubin J; Sideras K; Morris JC; McIver B; Burton JK; Webster KP; Bieber C; Traynor AM; Flynn PJ; Goh BC; Tang H; Ivy SP; Erlichman C; ; ;
    Lancet Oncol; 2010 Oct; 11(10):962-72. PubMed ID: 20851682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Refractory thyroid cancers].
    Schlumberger M; Chougnet C; Baudin E; Leboulleux S;
    Presse Med; 2011 Dec; 40(12 Pt 1):1189-98. PubMed ID: 22078085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF as a target for cancer therapy.
    Dienstmann R; Tabernero J
    Anticancer Agents Med Chem; 2011 Mar; 11(3):285-95. PubMed ID: 21426297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways.
    Gunda V; Bucur O; Varnau J; Vanden Borre P; Bernasconi MJ; Khosravi-Far R; Parangi S
    Cell Death Dis; 2014 Mar; 5(3):e1104. PubMed ID: 24603332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of ERK1/2 Causes Pazopanib Resistance via Downregulation of DUSP6 in Synovial Sarcoma Cells.
    Yokoyama N; Matsunobu T; Matsumoto Y; Fukushi JI; Endo M; Hatano M; Nabeshima A; Fukushima S; Okada S; Iwamoto Y
    Sci Rep; 2017 Mar; 7():45332. PubMed ID: 28350009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Src inhibitors in suppression of papillary thyroid carcinoma growth.
    Henderson YC; Toro-Serra R; Chen Y; Ryu J; Frederick MJ; Zhou G; Gallick GE; Lai SY; Clayman GL
    Head Neck; 2014 Mar; 36(3):375-84. PubMed ID: 23729178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Management of refractory thyroid cancers].
    Schlumberger M
    Ann Endocrinol (Paris); 2011 Apr; 72(2):149-57. PubMed ID: 21514562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A subset of papillary thyroid carcinomas contain KRAS mutant subpopulations at levels above normal thyroid.
    Myers MB; McKim KL; Parsons BL
    Mol Carcinog; 2014 Feb; 53(2):159-67. PubMed ID: 22930660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PDGFRα Regulates Follicular Cell Differentiation Driving Treatment Resistance and Disease Recurrence in Papillary Thyroid Cancer.
    Lopez-Campistrous A; Adewuyi EE; Benesch MGK; Ko YM; Lai R; Thiesen A; Dewald J; Wang P; Chu K; Ghosh S; Williams DC; Vos LJ; Brindley DN; McMullen TPW
    EBioMedicine; 2016 Oct; 12():86-97. PubMed ID: 27682510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.
    Paesler J; Gehrke I; Gandhirajan RK; Filipovich A; Hertweck M; Erdfelder F; Uhrmacher S; Poll-Wolbeck SJ; Hallek M; Kreuzer KA
    Clin Cancer Res; 2010 Jul; 16(13):3390-8. PubMed ID: 20570929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
    Byeon HK; Na HJ; Yang YJ; Ko S; Yoon SO; Ku M; Yang J; Kim JW; Ban MJ; Kim JH; Kim DH; Kim JM; Choi EC; Kim CH; Yoon JH; Koh YW
    Oncotarget; 2017 Jan; 8(1):596-609. PubMed ID: 27880942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer.
    Isham CR; Bossou AR; Negron V; Fisher KE; Kumar R; Marlow L; Lingle WL; Smallridge RC; Sherman EJ; Suman VJ; Copland JA; Bible KC
    Sci Transl Med; 2013 Jan; 5(166):166ra3. PubMed ID: 23283368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.